Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and dexamethasone (brand names include Decadron and Dexpak), results of a pivotal Phase 3 clinical trial suggest. The data were presented at the 2019 annual meeting of the…
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found. It may also identify patients more likely to benefit from inhibitors of blood vessel growth. The study, “Prognostic or predictive value of…
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those with full-blown disease — and may guide treatment choices toward a more personalized approach, a study shows. The study, “Single cell dissection…
Get regular updates to your inbox.